Freight Forwarder Flexport Raises $260 Million From Shopify
By Liz Young
Flexport's chief executive, Ryan Petersen, said Friday that the freight forwarder raised $260 million on an uncapped convertible note from Canadian e-commerce service provider Shopify.
A Flexport spokesperson didn't comment on how much cash the company has on hand or its plans for the funding.
San Francisco-based Flexport was most recently valued at $8 billion in a February 2022 fundraising round that pulled in $935 million.
Petersen has been making sweeping changes at the company over the past four months as he tries to return the business to profitability. Flexport's revenue fell sharply in 2023 as shipping prices plummeted amid weak shipping demand.
The latest fundraising deepens Flexport's relationship with Shopify after Flexport in May bought Shopify's logistics operation. Shopify as of September held a 17% stake in Flexport with a seat on Flexport's board.
Write to Liz Young at liz.young@wsj.com
(END) Dow Jones Newswires
January 21, 2024 19:22 ET (00:22 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track